首页> 外文期刊>Der Hautarzt; Zeitschrift fuer Dermatologie, Venerologie, und verwandte Gebiete >Molecular diagnosis of methicillin-resistent Staphylococcus aureus. Methods and efficacy
【24h】

Molecular diagnosis of methicillin-resistent Staphylococcus aureus. Methods and efficacy

机译:耐甲氧西林金黄色葡萄球菌的分子诊断。方法与功效

获取原文
获取原文并翻译 | 示例
           

摘要

Methicillin-resistant Staphylococcus aureus (MRSA) isolates are a serious public health problem whose ever-increasing rate is commensurate with the pressure it is exerting on the healthcare system. At present, more than 20 % of clinical S. aureus isolates in German hospitals are methicillin-resistant, in Austria less than 10 %. Strategies from low-prevalence countries show that this development is not necessarily inevitable. In the Scandinavian countries and the Netherlands, thanks to a rigorous prevention programme, MRSA prevalence has been kept at an acceptably low level (< 1-3 %). Central to these search-and-destroy control strategies is an admission screening using several MRSA swabs taken from mucocutaneous colonisation sites of high-risk patients (MRSA surveillance). It has also been reported that the speed with which MRSA carriage is detected has an important role, as it is a key component of any effective strategy to prevent the pathogen from spreading. Since MRSA culturing involves a 2-3 day delay before the final results are available, rapid detection techniques (commonly referred to as MRSA rapid tests) using polymerase chain reaction (PCR) methods and, most recently, rapid culturing methods have been developed. The implementation of rapid tests reduces the time of detection of MRSA carriers from 48-72 to 2-5 h. Clinical evaluation data have shown that MRSA can thus be detected with very high sensitivity. Specificity, however, is sometimes impaired due to false-positive PCR signals occurring in mixed flora specimens. In order to rule out false-positive PCR results, a culture screen must always be carried out simultaneously. The data provide preliminary evidence that a PCR assay can reduce nosocomial MRSA transmission in high-risk patients or high-risk areas, whereas an approach that screens all patients admitted to the hospital is probably not effective. Information concerning the cost effectiveness of rapid MRSA tests is still sparse and thus the issue remains debated.
机译:耐甲氧西林金黄色葡萄球菌(MRSA)分离株是一个严重的公共卫生问题,其不断增加的速率与其对医疗保健系统施加的压力相称。目前,德国医院中有超过20%的临床金黄色葡萄球菌分离株对甲氧西林耐药,而在奥地利不到10%。低流行国家的战略表明,这种发展并不一定是不可避免的。在斯堪的纳维亚国家和荷兰,由于严格的预防计划,MRSA的患病率一直保持在可接受的低水平(<1-3%)。这些搜索和销毁控制策略的核心是使用从高危患者的粘膜皮肤定植部位采集的几支MRSA拭子进行入院筛查(MRSA监测)。还已经报道,检测MRSA携带的速度具有重要作用,因为它是防止病原体扩散的任何有效策略的关键组成部分。由于MRSA培养需要2到3天的时间才能获得最终结果,因此使用聚合酶链反应(PCR)方法的快速检测技术(通常称为MRSA快速测试),最近开发了快速培养方法。快速测试的实施将MRSA载体的检测时间从48-72小时减少到2-5小时。临床评估数据表明,因此可以非常高的灵敏度检测MRSA。但是,有时由于混合菌群标本中出现假阳性PCR信号,有时会削弱特异性。为了排除PCR假阳性结果,必须始终同时进行培养筛选。数据提供了初步的证据,表明PCR检测可以减少高危患者或高危地区的医院内MRSA传播,而对所有入院患者进行筛查的方法可能无效。关于快速MRSA测试的成本效益的信息仍然很少,因此这个问题仍在争论中。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号